<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medroxyprogesterone acetate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medroxyprogesterone acetate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Medroxyprogesterone acetate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9600" href="/d/html/9600.html" rel="external">see "Medroxyprogesterone acetate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11787" href="/d/html/11787.html" rel="external">see "Medroxyprogesterone acetate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709035"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disorders (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen plus progestin therapy should not be used for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Long-term use (injection [contraceptive, endometriosis formulations]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Medroxyprogesterone is not recommended as a long-term (ie, longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Loss of bone mineral density (injection [contraceptive, endometriosis formulations]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Women who use medroxyprogesterone may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible. It is unknown if use of medroxyprogesterone during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk vs benefits (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and medroxyprogesterone acetate and other combinations and dosage forms of estrogens and progestins. Estrogens with progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192012"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Depo-Provera;</li>
<li>Depo-SubQ Provera 104;</li>
<li>Provera</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912143"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Depo-Provera;</li>
<li>Provera</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060100"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Contraceptive, Progestin Only</span>;</li>
<li>
<span class="list-set-name">Progestin</span></li></ul></div>
<div class="block dop drugH1Div" id="F192028"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb23a493-6b76-4451-83a9-7e07cc9e9369">Abnormal uterine bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding:</b> Adolescents: Oral: 5 to 10 mg for 5 to 10 days starting on day 16 or day 21 of menstrual cycle</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cae2cb0c-48ea-4bc7-a775-4b3fac907ba5">Amenorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amenorrhea:</b> Adolescents: Oral: 5 to 10 mg/day for 5 to 10 days</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b> Adolescents: First dose to be given only during first 5 days of normal menstrual period; only within 5 days postpartum if not breast-feeding, or only at sixth postpartum week if exclusively breast-feeding. When switching from other contraceptive methods, depo-subQ provera 104 should be administered within 7 days after the last day of using the last method (pill, ring, patch).</p>
<p style="text-indent:-2em;margin-left:4em;">IM (Depo-Provera): 150 mg every 3 months (every 13 weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ (depo-subQ provera 104): 104 mg every 3 months (every 12 to 14 weeks)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ff25425-526c-4be8-bbdd-66c0e5191fdb">Endometriosis-associated pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis-associated pain:</b> Adolescents: SubQ (depo-subQ provera 104): 104 mg every 3 months; treatment longer than 2 years is not recommended due to impact of long-term use on bone mineral density</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130659"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51130254"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with severe impairment. Discontinue with jaundice or if liver function disturbances occur. Consider lower dose or less frequent administration with mild to moderate impairment. Use of the contraceptive injection has not been studied in patients with hepatic impairment; consideration should be given to not readminister if jaundice develops.</p></div>
<div class="block doa drugH1Div" id="F192015"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9600" href="/d/html/9600.html" rel="external">see "Medroxyprogesterone acetate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fae0ae65-c96c-4591-ade4-935b592626f5">Abnormal uterine bleeding, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Hemodynamically unstable patients should generally be managed with surgical interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635706','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635706','lexi-content-ref-Zacur.1'])">Ref</a></span>). Typically used for hemodynamically stable patients with anovulatory bleeding and a thickened endometrium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Zacur.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> 10 to 20 mg 3 times a day for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-23635706','lexi-content-ref-9222474','lexi-content-ref-8459515','lexi-content-ref-17012455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-23635706','lexi-content-ref-9222474','lexi-content-ref-8459515','lexi-content-ref-17012455'])">Ref</a></span>). <b>Note: </b>Transition to maintenance dosing after resolution of acute bleeding (refer to dosing for “Abnormal uterine bleeding, nonacute”) or to another type of progestin (eg, levonorgestrel IUD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1','lexi-content-ref-18390083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1','lexi-content-ref-18390083'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aa64061-6e3a-4e32-801e-0989bd1fbc53">Abnormal uterine bleeding, nonacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, nonacute (alternative agent):</b>
<b>Note: </b>Dosing not intended for management of acute abnormal bleeding (ie, excessively heavy or prolonged bleeding that requires urgent evaluation). Alternative for patients who cannot or choose not to use preferred agents (eg, estrogen-progestin contraceptives, levonorgestrel IUD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>5 to 20 mg per day in 1 to 3 divided doses; adjust dose at 1- to 3-month intervals within this range to the lowest effective dose to control bleeding and minimize adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1','lexi-content-ref-18390083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1','lexi-content-ref-18390083'])">Ref</a></span>); some experts use up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>). <b>Note: </b>Continuous therapy is preferred in most patients due to increased efficacy and patient adherence; however, for patients who do not desire contraception, cyclic therapy (eg, administration only on days 5 to 26 of the menstrual cycle) may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception: Note:</b> Patients not currently using a hormonal contraceptive may receive the first dose at any time during the menstrual cycle if reasonably sure the patient is not pregnant. If administration is ≤7 days since menstrual bleeding started, no additional contraception is needed. If &gt;7 days since menstrual bleeding started, abstain from sexual intercourse, or <b>use additional contraceptive protection (nonhormonal) for the next 7 days</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>). Use is not recommended for long-term (ie, longer than 2 years) birth control unless other options are considered inadequate.</p>
<p style="text-indent:-2em;margin-left:4em;">Depo-Provera Contraceptive: <b>IM:</b> 150 mg every 3 months (every 13 weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">Depo-SubQ Provera 104: <b>SUBQ:</b> 104 mg every 3 months (every 12 to 14 weeks)</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Patients Switching from Another Contraceptive Method to Depo-medroxyprogesterone Acetate (DMPA) </b>
<b>104 mg/0.65 mL or 150 mg/mL Contraceptive Injection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> CDC [Curtis 2016a].</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Depo-Provera CI prescribing information.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Depo-SubQ Provera 104 prescribing information.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> Also refer to prescribing information for product-specific information.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">• DMPA may be initiated if it is reasonably sure the patient is not pregnant<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">• Ensure continuous contraceptive coverage based upon the mechanism of action of both contraception methods<sup>b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Current method</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Instructions for switching </b>
<b>to DMPA</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Combined oral contraceptive<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer first injection within 7 days of taking the last active tablet</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">DMPA- IM<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">When switching from the DMPA-IM to DMPA-SUBQ formulation, the DMPA-SUBQ dose should be administered 12 to 14 weeks after the last DMPA-IM injection</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Implant<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer first injection on day of implant removal</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Intrauterine device (IUD)<sup>a,c,d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">If sexual intercourse occurred since the start of the current menstrual cycle and it is &gt;5 days since menstrual bleeding began:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• Initiate DMPA and keep the IUD in place for ≥7 days before removing</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• Alternately, abstain from sexual intercourse or use barrier contraception for 7 days before removing the IUD and switching to DMPA</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• Consider use of emergency contraception if either option is not available (refer to guideline for details)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal system<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer first injection on day the next application would be scheduled</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vaginal insert<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer first injection on the day when the next insertion would be scheduled</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Use of Depo-medroxyprogesterone Acetate (DMPA) 104 mg/0.65 mL or 150 mg/mL Contraceptive Injection After Childbirth or Abortion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Use after childbirth</p></td>
<td align="center">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">Patients who are breastfeeding:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• The first injection may be administered the sixth week after birth (per manufacturer) or anytime &lt;1 month postpartum<sup>a,b,c</sup></p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• The first injection may be administered ≥1 month postpartum if it is reasonably certain the patient is not pregnant<sup>a</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">Patients who are not breastfeeding:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">• The first injection may be administered anytime it is reasonably certain the patient is not pregnant<sup>a</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">Patients ≥21 days postpartum who have not had a return of menses, or who are not fully or nearly fully breastfeeding should <b>abstain from sexual intercourse or use barrier contraception for the next 7 days<sup>a</sup></b></p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">Patients ≥21 days postpartum who have had a return of menses, but the injection is administered &gt;7 days since menstrual bleeding started should <b>abstain from sexual intercourse or use barrier contraception for the next 7 days<sup>a</sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Use after abortion</p></td>
<td align="center">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">The first DMPA injection may be administered within the first 7 days after a spontaneous or induced abortion<sup>a</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">DMPA may be administered immediately following a septic abortion<sup>d</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<b>Additional contraceptive protection (nonhormonal) is needed for the next 7 days </b>unless the injection is administered at the time of surgical abortion<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> CDC [Curtis 2016a].</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Depo-Provera CI prescribing information.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Depo-SubQ Provera 104 prescribing information.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> CDC [Curtis 2016b].</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Early or Late Doses of Depo-medroxyprogesterone Acetate (DMPA) 104 mg/0.65 mL or 150 mg/mL Contraceptive Injection<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> CDC [Curtis 2016a].</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">A repeat dose of DMPA may be administered early when necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Late dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">If &gt;2 weeks since dose was due (&gt;15 weeks since last injection) the injection may be administered if is reasonably certain the patient is not pregnant.</p>
<p style="text-indent:0em;text-align:left;">
<b>Additional contraceptive protection (nonhormonal) is needed for the next 7 days.</b></p>
<p style="text-indent:0em;text-align:left;">Consider use of emergency contraception if appropriate.</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c40ce17-9113-4ee8-9946-e0b153a8ac63">Endometrial carcinoma, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, recurrent or metastatic (adjunctive/palliative treatment):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM</b> (Depo-Provera): Initial: 400 to 1,000 mg/week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Canadian manufacturer's labeling: Usual dose: 200 to 400 mg daily. Doses &gt;200 mg daily may not confer additional benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10561210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10561210'])">Ref</a></span>). If improvement or disease stabilization occurs, 200 mg daily may be sufficient for maintenance. Discontinue use if no improvement within 2 to 3 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a991c81-a35c-4a19-b173-0ba7b3c10f15">Endometrial hyperplasia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial hyperplasia, treatment (off-label use): Note:</b> The optimal duration of therapy is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25932867','lexi-content-ref-22863972','lexi-content-ref-23090535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25932867','lexi-content-ref-22863972','lexi-content-ref-23090535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endometrial hyperplasia with atypia (also known as atypical endometrial hyperplasia or endometrial intraepithelial neoplasia</i>
<i>): </i>
<b>Oral:</b> 10 to 20 mg once daily (continuous dosing) <b>or</b> 10 to 20 mg once daily (cyclic dosing) for 12 to 14 days per month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25932867','lexi-content-ref-23090535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25932867','lexi-content-ref-23090535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endometrial hyperplasia without atypia (also known as </i>
<i>nonatypical endometrial hyperplasia or benign endometrial hyperplasia):</i>
<b>Oral:</b> 10 mg once daily (continuous dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24286192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24286192'])">Ref</a></span>) <b>or</b> 10 mg once daily (cyclic dosing) for 10 to 12 days per cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25797236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25797236'])">Ref</a></span>); continuous daily oral dosing was shown to be superior to cyclic oral dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24286192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24286192'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis (104 mg/0.65 mL injection):</b>
<b>SUBQ:</b> 104 mg every 3 months (every 12 to 14 weeks). <b>Note:</b> Use is not recommended for long-term (ie, longer than 2 years) endometriosis-associated pain unless other options are considered inadequate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0dc7166-0057-472c-ba10-74443d45e282">Estrogen therapy-associated endometrial hyperplasia, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Estrogen therapy-associated endometrial hyperplasia, prevention (alternative agent):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Indicated in patients with a uterus receiving estrogen therapy (eg, for vasomotor symptoms associated with menopause or secondary amenorrhea). May be administered either cyclically (preferred in late menopausal transition and early postmenopause or functional hypothalamic amenorrhea) or continuously (preferred if &gt;2 to 3 years postmenopause) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426619','lexi-content-ref-26444994','lexi-content-ref-28368518','lexi-content-ref-Martin.1','lexi-content-ref-35797481','lexi-content-ref-19196677','lexi-content-ref-24905063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426619','lexi-content-ref-26444994','lexi-content-ref-28368518','lexi-content-ref-Martin.1','lexi-content-ref-35797481','lexi-content-ref-19196677','lexi-content-ref-24905063'])">Ref</a></span>). Discontinue when estrogen therapy is discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 to 10 mg daily for 10 to 14 days each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ackerman.1','lexi-content-ref-28426619','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ackerman.1','lexi-content-ref-28426619','lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>2.5 to 5 mg daily continuously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426619'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40029beb-aba6-467e-b908-d4431aca5c40">Secondary amenorrhea, diagnostic aid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, diagnostic aid ("progestin challenge"): Oral:</b> 5 to 10 mg daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24463911','lexi-content-ref-28368518','lexi-content-ref-32041389','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24463911','lexi-content-ref-28368518','lexi-content-ref-32041389','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Withdrawal bleeding may be expected during therapy or within 3 to 7 days after cessation of therapy; absence of withdrawal bleeding suggests low endometrial estrogen exposure and/or uterine or outflow tract abnormality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24463911','lexi-content-ref-28368518','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24463911','lexi-content-ref-28368518','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990546"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987881"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Medroxyprogesterone is extensively metabolized in the liver and elimination is significantly reduced in patients with advanced hepatic disease. Most products are contraindicated in patients with hepatic impairment. If needed for the palliative treatment metastatic endometrial carcinoma, monitor closely; withhold or discontinue treatment if liver dysfunction develops and do not resume until hepatic function has returned to normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Discontinue if jaundice develops or if acute or chronic hepatic function disturbances occur; do not resume until liver function returns to normal. In patients with a history of cholestatic jaundice, discontinue if cholestatic jaundice recurs.</p></div>
<div class="block arsc drugH1Div" id="F57160581"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various degrees of bone loss with medroxyprogesterone use have been reported in the literature with most estimates ~1% to 4% <b>decreased bone mineral density </b>(BMD) at the hip and spine after 1 year, ~6% to 8% after 2 years, and ~5% after 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24848921','lexi-content-ref-31479152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24848921','lexi-content-ref-31479152'])">Ref</a></span>). Data are lacking to conclude that the surrogate marker of decreased BMD translates to increased fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24848921','lexi-content-ref-32973688','lexi-content-ref-24960023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24848921','lexi-content-ref-32973688','lexi-content-ref-24960023'])">Ref</a></span>). Current evidence suggests that changes in BMD may be transient, similar to changes observed during pregnancy or lactation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24960023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24960023'])">Ref</a></span>). Some studies report full recovery of bone loss 1 to 5 years after medroxyprogesterone discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24848921','lexi-content-ref-31479152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24848921','lexi-content-ref-31479152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; while the exact mechanism remains unclear, proposed hypotheses include changes in estrogen and/or insulin like growth factors (IGFs) eliciting alteration of osteoclast activity and bone formation; and decreased proliferation of osteoblasts due to glucocorticoid action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32973688','lexi-content-ref-31479152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32973688','lexi-content-ref-31479152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; decreases in BMD have been observed after 1 year of therapy with the most impact within the first 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32973688','lexi-content-ref-24960023','lexi-content-ref-31479152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32973688','lexi-content-ref-24960023','lexi-content-ref-31479152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Current versus prior use of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24960023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24960023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (some studies cite increased risk with therapy duration &gt;2 years and others cite &gt;4 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32973688','lexi-content-ref-24960023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32973688','lexi-content-ref-24960023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral medroxyprogesterone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32973688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32973688'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Adolescents and young adult females (eg, use prior to 20 years of age), and females &gt;50 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32973688','lexi-content-ref-24960023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32973688','lexi-content-ref-24960023'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Menstrual bleeding irregularities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Medroxyprogesterone is commonly associated with <b>gynecological bleeding</b>, including irregular or unpredictable bleeding patterns, breakthrough bleeding, <b>spotty menstruation</b>, heavy bleeding, prolonged bleeding, and<b> amenorrhea </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24146298','lexi-content-ref-11057840','lexi-content-ref-30633132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24146298','lexi-content-ref-11057840','lexi-content-ref-30633132'])">Ref</a></span>). Rates of menstrual bleeding irregularities decrease with longer duration of use. While menstrual bleeding irregularities are common, they rarely have precarious health implications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12046776'])">Ref</a></span>). However, the unpredictability of bleeding may lead to discontinuation, potentially leading to unplanned pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24146298','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24146298','lexi-content-ref-12046776'])">Ref</a></span>). According to the manufacturer, ~8% of subjects discontinued intramuscular medroxyprogesterone due to menstrual bleeding irregularities, while ~3% discontinued subcutaneous medroxyprogesterone. Counseling on the anticipated bleeding irregularities has been associated with a higher rate of therapy continuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24146298','lexi-content-ref-16904417','lexi-content-ref-11368986','lexi-content-ref-30633132','lexi-content-ref-8773423','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24146298','lexi-content-ref-16904417','lexi-content-ref-11368986','lexi-content-ref-30633132','lexi-content-ref-8773423','lexi-content-ref-12046776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; maybe due to changes in the endometrium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11057840','lexi-content-ref-16904417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11057840','lexi-content-ref-16904417'])">Ref</a></span>); however, the exact mechanism has not been elucidated as various interventions for management have yielded little consistency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24146298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24146298'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; menstrual bleeding irregularities are highest during the first year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24146298','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24146298','lexi-content-ref-12046776'])">Ref</a></span>). Users are more likely to experience amenorrhea with longer duration of use, which may be perceived as a positive adverse reaction, leading to less reported complaints of menstrual bleeding irregularities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16904417','lexi-content-ref-30633132','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16904417','lexi-content-ref-30633132','lexi-content-ref-12046776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy/number of injections received: breakthrough bleeding and spotting decrease with continued use while amenorrhea becomes more common (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16904417','lexi-content-ref-12046776','lexi-content-ref-11156873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16904417','lexi-content-ref-12046776','lexi-content-ref-11156873'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A mean <b>weight gain of </b>&lt;2 kg was reported during the first year of intramuscular (IM) medroxyprogesterone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33898953','lexi-content-ref-27567593','lexi-content-ref-31928370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33898953','lexi-content-ref-27567593','lexi-content-ref-31928370'])">Ref</a></span>). After 2 to 4 years, weight gain at least doubled with an increase of 4 to 10 kg reported with IM use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33898953','lexi-content-ref-27567593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33898953','lexi-content-ref-27567593'])">Ref</a></span>). It is inconclusive if weight gain is directly related to the drug or normal weight gain over time, independent of contraceptive use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27567593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27567593'])">Ref</a></span>). Weight gain is cited as one of the most common reasons for discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27567593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27567593'])">Ref</a></span>). Counseling on typical weight gain and the importance of a healthy lifestyle may decrease discontinuation rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31019626','lexi-content-ref-29694506','lexi-content-ref-24784333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31019626','lexi-content-ref-29694506','lexi-content-ref-24784333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose related; may be due to hormone-mediated changes in fat deposition (Yancey 2014). More sources agree that the etiology of weight gain is unclear and may be independent of contraceptive use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33898953','lexi-content-ref-29694506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33898953','lexi-content-ref-29694506'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; reported most after 1 year of use and increases with continued therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33898953','lexi-content-ref-27567593','lexi-content-ref-31928370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33898953','lexi-content-ref-27567593','lexi-content-ref-31928370'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (IM): </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27567593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27567593'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Early excessive (&gt;5% increase from baseline weight) weight gain maybe a predictor for continued weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31019626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31019626'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nulliparity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31019626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31019626'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Unmarried status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31019626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31019626'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior use of IM medroxyprogesterone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31019626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31019626'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31928370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31928370'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underweight at initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31928370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31928370'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F191981"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse effects as reported with any dosage form.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (6% to 68%), hot flash (≤36%), weight gain (7% to 38%), weight loss (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gynecological bleeding (IM: 32% to 57%; SUBQ: 18%; including irregular, increase or decrease flow, and spotting)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (9% to 17%), nervousness (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (1% to 4%), alopecia (1%), skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bloating (2%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bacterial vaginosis (≤5%), breast tenderness (≤2%), dysmenorrhea (≤2%), leukorrhea (3%), mastalgia (≤3%), urinary tract infection (4%), vaginitis (≤5%), vulvovaginal candidiasis (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Atrophy at injection site (≤1%), induration at injection site (≤1%), injection-site reaction (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (1%), asthenia (≤4%), depression (2% to 3%), dizziness (1% to 6%), fatigue (≤4%), insomnia (1%), irritability (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1%), back pain (2% to 3%), lower limb cramp (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention, galactorrhea not associated with childbirth</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dyspareunia, lump in breast</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, facial nerve paralysis, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cushing syndrome, decreased glucose tolerance, hypercalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Change in cervical erosion, change in cervical secretions, nipple discharge</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site nodule, skin discoloration at injection site, tenderness at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, euphoria, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lipodystrophy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis, retinal thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis, pulmonary embolism, thrombophlebitis, varicose veins</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Chloasma, diaphoresis, skin discoloration (melasma)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism, increased libido, increased thirst, spotty menstruation (Abdel-Aleem 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anovulation (prolonged), breast changes, delayed return to fertility, genitourinary infection, lactation insufficiency, malignant neoplasm of breast, malignant neoplasm of cervix, nipple bleeding, uterine hyperplasia, vaginal cyst</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Lestishock 2011), angioedema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Residual mass at injection site, sterile abscess at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Axillary swelling, decreased bone mineral density (Quintino-Moro 2019), osteoporosis, pathological fracture due to osteoporosis, systemic sclerosis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F191995"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection (104 mg/0.65 mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of); cerebral vascular disease; undiagnosed vaginal bleeding; breast cancer (known, suspected, or history of); significant hepatic disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection (150 mg/mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of) or cerebral vascular disease; undiagnosed vaginal bleeding; breast cancer (known, suspected, or history of); significant hepatic disease; pregnancy; diagnostic test for pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection (400 mg/mL): Hypersensitivity to medroxyprogesterone or any component of the formulation; active thrombophlebitis; thromboembolic disorders (current or history of); cerebral vascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Anaphylactic reaction or angioedema to medroxyprogesterone; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); estrogen- or progesterone-dependent tumor (known or suspected) (excludes Canadian product indicated for endometrial cancer); undiagnosed abnormal genital bleeding; breast cancer (known, suspected, or history of); hepatic impairment or disease; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Injection (50 mg/mL, 150 mg/mL): History of or current benign or malignant liver tumors; current or history of migraine with focal aura; any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields; undiagnosed breast pathology; known or suspected progestin-dependent neoplasia; MI or coronary artery disease (current or history of); urinary tract bleeding; presence of severe or multiple risk factors for arterial or venous thrombosis including the following: severe hypertension (persistent bp ≥160/100 mm Hg); hereditary or acquired predisposition for venous or arterial thrombosis (eg, Factor V leiden and Prothrombin G20210 A mutation, activated protein C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinanemia and antiphospholipid-antibodies (anticardiolipin antibodies, lupus anticoagulant); severe dyslipoproteinemia; heavy smoking (&gt;15 cigarettes per day) and older than 35 years of age; diabetes mellitus with vascular involvement.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Partial or complete loss of vision due to ophthalmic vascular disease.</p></div>
<div class="block war drugH1Div" id="F191978"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause suppression of hypothalamic-pituitary-adrenal (HPA) axis, resulting in decreased plasma cortisol concentrations, decreased cortisol secretion, and low plasma ACTH concentrations. Cushingoid symptoms may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Anaphylaxis or anaphylactoid reactions have been reported with use of the injection; medication for the treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: The risk of breast cancer in postmenopausal patients on hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Most studies do not see an increased risk of breast cancer following medroxyprogesterone use for contraception (Chelmow 2020). However, breast cancer is a hormonal sensitive tumor and the prognosis for patients with a current or recent history of breast cancer may be worse with progestin-only contraceptive use (CDC [Curtis 2016b]). Use of medroxyprogesterone for the treatment of endometrial carcinoma is not recommended in patients with known or suspected breast cancer; carefully monitor patients with a strong family history of breast cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ectopic pregnancy: When used for contraception, consider the possibility of ectopic pregnancy in patients with severe abdominal pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial hyperplasia: MPA is used to reduce the risk of endometrial hyperplasia in nonhysterectomized postmenopausal patients receiving conjugated estrogens. MPA is not the preferred progesterone for this indication (AACE [Goodman 2011]; AACE/ACE [Cobin 2017]). The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestogen to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated, to rule out malignancy in postmenopausal patients with undiagnosed abnormal vaginal bleeding. The use of a progestogen is not generally required when low doses of estrogen are used locally for vaginal atrophy, although long-term data (&gt;1 year) supporting this recommendation are lacking (NAMS 2020; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertriglyceridemia: In patients using estrogen plus progesterone therapy, triglycerides may be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (AACE [Goodman 2011]; ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use with caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Manage risk factors for cardiovascular disease (eg, diabetes mellitus, hypercholesterolemia, hypertension, systemic lupus erythematosus [SLE], obesity, tobacco use, and/or history of venous thromboembolism [VTE]) appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. When used for contraception, use caution in patients with risk factors for cardiovascular disease (CDC [Curtis 2016b]). If thrombosis develops with contraceptive treatment, discontinue treatment (unless no other acceptable contraceptive alternative).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (AACE [Goodman 2011]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Monitor patients with a history of depression; consider discontinuing if depression recurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Medroxyprogesterone therapy may have adverse effects on glucose tolerance; monitor patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use with caution in patients with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Use caution in patients with a history of cholestatic jaundice associated with prior estrogen use or pregnancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use estrogen plus progestogen therapy with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroidism: Use estrogen plus progestogen therapy with caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution in patients with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use estrogen plus progestogen therapy with caution in patients with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: Use estrogen plus progestogen therapy with caution in patients with SLE; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: Dose adjustment of depo-medroxyprogesterone 150 mg/mL IM or 104 mg/0.65 mL SUBQ contraceptive injections is not required based on body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue progestogens in combination with estrogens at least 4 to 6 weeks prior to surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abnormal uterine bleeding: When considering specific treatment for acute or chronic abnormal uterine bleeding due to ovulatory dysfunction (not structural causes), consider medical contraindications to available therapies as well as if simultaneous contraception is needed or pregnancy is desired (ACOG 2013a; ACOG 2013c).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial carcinoma: When used for endometrial carcinoma, the effects of long-term use on adrenal, hepatic, ovarian, pituitary, and uterine function is not known. Use for endometrial carcinoma may mask the onset of menopause.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection protection: Injectable contraceptives do not protect against HIV infection or other sexually transmitted diseases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Menopause: When used for the relief of menopausal symptoms, the benefit-risk of combination hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Consider cardiovascular disease risk factors when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Estrogens with progestogen should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual patient.</p></div>
<div class="block foc drugH1Div" id="F191989"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Provera: 150 mg/mL (1 mL) [contains methylparaben, polyethylene glycol, polysorbate 80, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Provera: 400 mg/mL (2.5 mL) [contains polyethylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Provera: 150 mg/mL (1 mL) [contains methylparaben, polyethylene glycol, polysorbate 80, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-SubQ Provera 104: 104 mg/0.65 mL (0.65 mL) [contains methylparaben, polyethylene glycol, polysorbate 80, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provera: 2.5 mg, 5 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provera: 5 mg [contains corn starch, fd&amp;c blue #2 aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provera: 10 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F191974"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F191996"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Depo-Provera Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $63.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (medroxyPROGESTERone Acetate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $41.27 - $97.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Depo-Provera Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $65.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Depo-SubQ Provera 104 Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">104 mg/0.65 mL (per 0.65 mL): $63.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (medroxyPROGESTERone Acetate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $66.00 - $115.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (medroxyPROGESTERone Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Provera Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $3.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $4.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $6.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52912144"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, IM, as acetate:</p>
<p style="text-indent:-2em;margin-left:4em;">Depo-Provera: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral, as acetate: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Provera: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block admp drugH1Div" id="F52613238"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral: Administer with food </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IM: (Depo-Provera Contraceptive): Shake suspension vigorously; administer by deep IM injection in the gluteal or deltoid muscle</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SubQ (depo-subQ provera 104): Shake vigorously for at least 1 minute; administer by subQ injection slowly over 5 to 7 seconds in the anterior thigh or abdomen; avoid boney areas and the umbilicus. Do not rub the injection area; not for IM or IV use. </p></div>
<div class="block adm drugH1Div" id="F191992"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Depo-Provera Contraceptive: Administer first dose during the first 5 days of menstrual period, or within the first 5 days postpartum if not breastfeeding, or at the sixth week postpartum if breastfeeding exclusively. Shake vigorously prior to administration. Administer by deep IM injection in the gluteal or deltoid muscle. Rotate administration site with each injection. Injection must be administered by a health care professional only. Patients should return every 3 months (range: 10 to 13 weeks) for subsequent doses; the interval between injections should not exceed 13 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Depo-SubQ Provera 104: Administer first dose during the first 5 days of menstrual period, or at the sixth week postpartum if breastfeeding. Shake vigorously for at least 1 minute prior to administration. Administer by SUBQ injection in the upper anterior thigh or abdomen; avoid boney areas and the umbilicus. Administer slowly over 5 to 7 seconds. Do not rub the injection area. Rotate administration site with each injection. Product labeling recommends the SUBQ injection be administered by a health care professional; however, patient administration is also an option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34014910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34014910'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132797"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F1972742"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53567690"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Secondary amenorrhea or abnormal uterine bleeding due to hormonal imbalance; prevention of pregnancy; reduction of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens; endometrial carcinoma; management of endometriosis-associated pain (FDA approved in adults) </p></div>
<div class="block mst drugH1Div" id="F192043"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Depo-Provera may be confused with DEPO-Medrol, depo-subQ provera 104</p>
<p style="text-indent:-2em;margin-left:4em;">MedroxyPROGESTERone may be confused with HYDROXYprogesterone caproate, methylPREDNISolone, methylTESTOSTERone</p>
<p style="text-indent:-2em;margin-left:4em;">Provera may be confused with Covera, Femara, Parlodel, Premarin, Proscar, PROzac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The injectable dosage form is available in different formulations. Carefully review prescriptions to assure the correct formulation and route of administration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F192030"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F191983"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with aprepitant, and to continue back-up contraception for 28 days after discontinuing aprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asparaginase Products: Hormonal Contraceptives may enhance the thrombogenic effect of Asparaginase Products.  Management: Consider discontinuing hormonal contraceptives and using an alternative contraceptive method in patients treated with asparaginase products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May decrease the serum concentration of Hormonal Contraceptives. Management: Use of a high-dose oral contraceptive (at least 30 mcg of ethinyl estradiol combined with norethindrone) is recommended when combined with asunaprevir. Consider an additional barrier method when other forms of contraception are used with asunaprevir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, atazanavir/ritonavir may decrease concentrations of estrogens. Atazanavir may increase the serum concentration of Hormonal Contraceptives. Specifically, atazanavir alone may increase concentrations of estrogens and atazanavir alone or boosted may increase concentrations of progestins. Management: Dose adjustment of hormonal contraceptives or use of alternative or additional nonhormonal contraceptive may be needed when combined with atazanavir. See full interact monograph for details. Atazanavir/cobicistat with drospirenone is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a non-hormonal contraceptive during brigatinib use and for at least 4 months after the last brigatinib dose. Males with partners of reproductive potential should use contraception during treatment with brigatinib and for 3 months after brigatinib use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carfilzomib: Hormonal Contraceptives may enhance the thrombogenic effect of Carfilzomib.  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may decrease serum concentrations of estrogens. Cobicistat may increase the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may increase serum concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with cobicistat. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the adverse/toxic effect of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a back-up method during coadministration, and to continue back-up contraception for 12 weeks after stopping efavirenz to ensure contraceptive reliability. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Hormonal Contraceptives may diminish the therapeutic effect of Elagolix. Specifically, estrogen-containing hormonal contraceptives may diminish the therapeutic effects of elagolix. Elagolix may decrease the serum concentration of Hormonal Contraceptives. Specifically, concentrations of progestins may be decreased with elagolix therapy. Elagolix may increase the serum concentration of Hormonal Contraceptives. Specifically, concentrations of ethinyl estradiol may be increased with elagolix therapy.  Management: Use an alternative, nonhormonal contraceptive during treatment with elagolix and for at least 28 days following discontinuation of elagolix treatment. Use of elagolix 200 mg twice daily with an estrogen-containing hormonal contraceptive is not recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: Hormonal Contraceptives may enhance the adverse/toxic effect of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the risk for rash may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Hormonal Contraceptives. Specifically, progestin concentrations may decrease. Etravirine may increase the serum concentration of Hormonal Contraceptives. Specifically, estrogen concentrations may increase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide: Hormonal Contraceptives may diminish the therapeutic effect of Exenatide. Exenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives at least one hour prior to exenatide. Monitor blood glucose more frequently when patients treated with exenatide initiate therapy with a hormonal contraceptive. Increases in exenatide doses may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing felbamate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: Hormonal Contraceptives may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with fosaprepitant, and to continue back-up contraception for 28 days after discontinuing fosaprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing griseofulvin to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of Hormonal Contraceptives. Management: Consider alternative methods of contraception (ie, non-hormonal) in patients receiving ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: May decrease the serum concentration of Hormonal Contraceptives. More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of hormonal contraceptives. Management: Patients of reproductive potential should use a non-hormonal contraceptive method during treatment with ixazomib and for at least 90 days after the last ixazomib dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lixisenatide: Hormonal Contraceptives may diminish the therapeutic effect of Lixisenatide. Lixisenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives 1 hour before or at least 11 hours after administration of lixisenatide. Additionally, monitor blood glucose more frequently when patients treated with lixisenatide initiate therapy with a hormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative contraceptive that is not sensitive to CYP3A4 induction or a back-up method during coadministration, and to continue back-up contraception for 4 months after stopping mavacamten to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Nonhormonal contraception should be used during, and for 4 weeks following, mifepristone treatment for hyperglycemia due to Cushing syndrome. If used for pregnancy termination, hormonal contraceptives can be used after pregnancy expulsion is confirmed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: May decrease the serum concentration of Hormonal Contraceptives. Management: Effective nonhormonal contraception is recommended for those of reproductive potential during treatment with mitotane as well as after discontinuation of mitotane for as long as mitotane plasma levels are detectable.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients of childbearing potential who are taking hormonal contraceptives should use an additional form of barrier contraception during treatment with mycophenolate and for 6 weeks after mycophenolate discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may decrease concentrations of estrogens. Nirmatrelvir and Ritonavir may increase the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may increase concentrations of progestins. Management: Use additional nonhormonal forms of contraception (back-up method) when estrogen-containing hormonal contraceptives are combined with nirmatrelvir/ritonavir. Progestin-only contraceptives can be used without back-up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May decrease the serum concentration of Hormonal Contraceptives. Management: Women should use an alternative non-hormonal method of contraception or a back-up method when octreotide is combined with hormonal contraceptives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Avoid use of olutasidenib with sensitive or narrow therapeutic index CYP3A4 substrates when possible. If concurrent use with olutasidenib is unavoidable, monitor closely for evidence of decreased concentrations of the CYP3A4 substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing oxcarbazepine to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: MedroxyPROGESTERone may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients should use an alternative, nonhormonal-based form of contraception during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with pitolisant and for at least 21 days after discontinuation of pitolisant treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may decrease concentrations of estrogens. Protease Inhibitors may increase the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may increase concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with protease inhibitors. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: May decrease the serum concentration of Hormonal Contraceptives. Management: Individuals of childbearing potential should use a non-hormonal contraceptive method during treatment with tazemetostat and for 6 months after. Males with partners of childbearing potential should use contraception during treatment and for 3 months after.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: May decrease the serum concentration of Hormonal Contraceptives. Management: Product labeling recommends that patients taking hormonal contraceptives should use an additional, non-hormonal contraceptive or reliable barrier method during treatment with tetrahydrocannabinol and cannabidiol buccal spray.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Hormonal Contraceptives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation of tirzepatide and for 4 weeks after each dose escalation of tirzepatide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing topiramate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Hormonal Contraceptives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing meropenem/vaborbactam to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Hormonal Contraceptives may increase the serum concentration of Vitamin K Antagonists. Hormonal Contraceptives may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Hormonal Contraceptives may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F192007"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Bioavailability of the oral tablet is increased when taken with food; half-life is unchanged. Management: Administer without regard to food.</p></div>
<div class="block dic drugH1Div" id="F191999"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake</p></div>
<div class="block rep_considerations drugH1Div" id="F49308128"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Depo-medroxyprogesterone 104 mg/0.65 mL and 150 mg/mL injections are used for contraception. Use is not recommended as a long-term (ie, longer than 2 years) birth control method unless other options are considered inadequate.</p>
<p style="text-indent:0em;margin-top:2em;">All available forms of contraception, including depo-medroxyprogesterone acetate (DMPA) injection, can be considered for patients on gender-affirming testosterone therapy after evaluating patient preferences and medical conditions (Bonnington 2020; Krempasky 2020). DMPA may help induce amenorrhea more rapidly than other progestin-only methods when testosterone is initiated. DMPA may cause weight gain; other forms of contraception may be preferred for patients already experiencing weight gain with testosterone therapy (Bonnington 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Median time to conception/return to ovulation following discontinuation of DMPA contraceptive injection is 10 months following the last injection and is unrelated to the duration of use.</p>
<p style="text-indent:0em;margin-top:2em;">High doses of medroxyprogesterone used for indications other than contraception would be expected to impair fertility.</p></div>
<div class="block pri drugH1Div" id="F191997"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In general, there is not an increased risk of birth defects following inadvertent use of the injectable depo-medroxyprogesterone acetate (DMPA) contraceptives early in pregnancy. Hypospadias has been reported in male babies, and clitoral enlargement and labial fusion have been reported in female babies exposed to medroxyprogesterone during the first trimester of pregnancy. When used for contraception, consider the possibility of ectopic pregnancy in patients with severe abdominal pain; ectopic pregnancies have been reported with use of the DMPA contraceptive injection.</p></div>
<div class="block mopp drugH1Div" id="F53567691"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate prior to administration of MPA contraceptive injection; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision; sudden onset of proptosis, diplopia, or migraine; signs and symptoms of thromboembolic disorders; signs and symptoms of depression; glucose in patients with diabetes; or blood pressure. BMD with long-term use. </p>
<p style="text-indent:0em;margin-top:2em;">Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.</p></div>
<div class="block pha drugH1Div" id="F191977"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Medroxyprogesterone acetate (MPA) transforms a proliferative endometrium into a secretory endometrium. When administered with conjugated estrogens, MPA reduces the incidence of endometrial hyperplasia and risk of adenocarcinoma. When used as an injection for contraception (doses of 150 mg IM or 104 mg SubQ), MPA inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation and causes endometrial thinning. Progestogens, such as medroxyprogesterone when used for endometriosis, lead to atrophy of the endometrial tissue. They may also suppress new growth and implantation. Pain associated with endometriosis is decreased (ASRM 2014).</p></div>
<div class="block phk drugH1Div" id="F191994"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Time to ovulation (after last injection): 10 months (range: 6 to 12 months)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid; IM: Slow</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 86% to 90% primarily to albumin; does not bind to sex hormone-binding globulin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via hydroxylation and conjugation; forms metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 0.6% to 10%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: 12 to 17 hours; IM (Depo-Provera Contraceptive): ~50 days; SubQ: ~43 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: 2 to 4 hours; IM (Depo-Provera Contraceptive): ~3 weeks; SubQ: ~1 week</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192000"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-medroxy | Depo provera | Farlutal | Provera</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cycrin | Depo provera | Farlutale | Farlutale an | Livomedrox | Map an | Medrosterona | Medroxiprogesterona | Medroxiprogesterona gp pharm</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Depocon | Farlutal | Prodafem | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Depo ralovera | Medroxyhexal | Medroxyprogesterone | Provera | Ralovera</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Medogen | Medrina | Medrogest | Medroxy | Perlutex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera | Sayana | Veraplex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Sayana press</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Medroxyprogesteron | Provera</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acemedrox | Acetoflux | Contracep | Cycrin | Demedrox | Depo provera | Farlutal | Farlutal ad | Medroxitest | Procept | Progesan | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Prodafem | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Depo subq provera | Sayana press</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Farlutal | Medroxiprogesterona | Medroxiprogesterone | Prodasone | Sayana | Sayana press | Sicrit</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei en | Depo Geston | Depo provera | Farlutal | Medroxyprogesteron | Provera</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Ileine | Medroxiprogesteron | Medroxiprogesterona | Medroxiprogesterone | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Medroplex | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clinofem | Clinovir | Depo clinovir | Depo progevera | Depo provera | Farlutal | Mpa | Mpa gyn | Sayana</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Depotrim | Medroxiprogesterona | Perlutex | Progest amina | Progestagen | Provera</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Depotrim | Provera | Solutres</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cycrina | Depo provera | Depocon | Farlutal | Perlutex | Provera | Veraplex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Megestron | Oxyprogest | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Depo progevera | Farlutal | Progevera</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Triclovera</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cykrina | Depo provera | Farlutal | Gestapuran | Lutopolar | Mepastat | Provera</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Depo prodasone | Depo provera | Farlutal | Gestoral | Prodasone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adgyn medro | Climanor | Depo provera | Farlutal | Medroxyprogesteron kent pharm | Provera | Sayana Press Uniject</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Gestoral | Progevera | Provera</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-medroxy | Farlutal | Fuan | Novo-Medrone | Provera | Triclofem</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Provera</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Andalan | Depo Geston | Depo harmonis | Depo progestin | Depo provera | Deponeo | Farlutal | Planibu | Prothyra | Provera | Triclofem | Veraplex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aragest | Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Db | Depo provera | Deviry | Dub | Dubloc | Embryogen | Empeea | Maxogest | Medanin | Medolin | Medona | Medrogest | Medronorm | Medtet | Megest | Megestone | Meprate | Modus | Myone | Orgamed | Petogen | Provera | Regeeva | Sayana press</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera | Provera g</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asconale e | Hysron | Hysron h | Hysron pfizer | Medkiron | Medroxyprogesterone acetate f | Nerfin | Progeston | Provera</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Db | Depo provera | Mepro sterone | Mygesty | Petogen | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cycrin | Cymeron | Depo provera | Farlutal | Farutal | Medrogen | Menopause | Progen | Progerone | Prosgen | Provera | Sayana | Veraplex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo-medroxy | Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Perlutex | Provera</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cykrina | Depo clinovir | Depo provera | Farlutal | Perlutex | Provera</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cykrina | Depo progevera | Depo provera | Depocon | Farlutal | Perlutex | Provera</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ciclotal | Cycrin | Depo provera | Farlutal | Medroxiprogesterona | Megestron | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Condep | Depo provera | Deviry | Farlutal | Non-Preg | Provera | Ravimed | Veraplex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Medroxyprogest | Medroxyprogesteronacetaat | Megestron | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Perlutex | Provera</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clinotrin 3 | Depo provera | Drokse | Drokse 3 | Medroges | Medroxiprogest | Medroxiprogesterona | Meprogen | Provera | Sayana | Solutres</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Db | Depo provera | Depofemme | Deporeva | Lyndavel | Medroxcure | Provera | Provestin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ciclotal | Depo provera | Depo queen | Depotone | Famila | Medrosterona | Megestron | Roxyprog depo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Gestomikron | Provera</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amen | Cycrin | Depo provera | Depo subq provera | Medroxyprogesteron | Medroxyprogesteron acetate | Medroxyprogesterone | Provera</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Medroxiprogesterona | Provera</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Medroxine | Medroxiprogesterona l.ch</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Depo-Provera | Provera</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Farlutal | Sayana</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ciclotal | Depo provera | Medroxyproges lens | Provera | Veraplex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-medroxy | Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Provera</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Medroplex | Provera</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Depo provera</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Contracep | Controlan | D.m.p.a | Depo a | Depo m | Depo Progesno | Depo progesta | Depo provera | Depo provin | Depogestin | Depomoxie | Enaf-150 | Farlutal | Ladeesaef | Manodepo | Medeton | Medomax | Medroxyprogesteron | Mpa | Nomora | Non-Preg | Provera | Veraplex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Depo prodasone | Depo provera | Farlutal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Tarlusal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Fuan | Medorone | Medrone | Mepro | Meterone | Neolut | Provera | Puromin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Provera</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Sayana press</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">M.p.a | Medrosterona | Medroxine | Provera</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cycrin | Depo provera | Farlutal | Provera | Sayana</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Farlutal | Medroxyprogest Fresenius | Medroxyprogesteron | Petogen | Provera | Sayana | Triclofem</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Depo provera | Deviry | Hexal mpa | Provera | Sayana</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HD.2020">
<a name="HD.2020"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF-38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24146298">
<a name="24146298"></a>Abdel-Aleem H, d'Arcangues C, Vogelsong KM, Gaffield ML, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. <i>Cochrane Database Syst Rev</i>. 2013 Oct 21;(10):CD003449. doi:10.1002/14651858.CD003449.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24146298/pubmed" id="24146298" target="_blank">24146298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25797236">
<a name="25797236"></a>Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. <i>Am J Obstet Gynecol</i>. 2015;213(4):469-478. doi:10.1016/j.ajog.2015.03.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/25797236/pubmed" id="25797236" target="_blank">25797236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ackerman.1">
<a name="Ackerman.1"></a>Ackerman KE, Misra M. Functional hypothalamic amenorrhea: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31603998">
<a name="31603998"></a>Ackerman KE, Singhal V, Slattery M, et al. Effects of estrogen replacement on bone geometry and microarchitecture in adolescent and young adult oligoamenorrheic athletes: a randomized trial. <i>J Bone Miner Res.</i> 2020;35(2):248-260. doi:10.1002/jbmr.3887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31603998/pubmed" id="31603998" target="_blank">31603998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9222474">
<a name="9222474"></a>Aksu F, Madazli R, Budak E, Cepni I, Benian A. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. <i>Aust N Z J Obstet Gynaecol</i>. 1997;37(2):228-231. doi:10.1111/j.1479-828x.1997.tb02260.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/9222474/pubmed" id="9222474" target="_blank">9222474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441825">
<a name="31441825"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 785: Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. <i>Obstet Gynecol</i>. 2019;134(3):e71-e83. doi:10.1097/AOG.0000000000003411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31441825/pubmed" id="31441825" target="_blank">31441825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36356248">
<a name="36356248"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Gynecology. General approaches to medical management of menstrual suppression: ACOG Clinical Consensus No. 3. <i>Obstet Gynecol.</i> 2022;140(3):528-541. doi:10.1097/AOG.0000000000004899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/36356248/pubmed" id="36356248" target="_blank">36356248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23787936">
<a name="23787936"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 136: Management of abnormal uterine bleeding associated with ovulatory dysfunction. <i>Obstet Gynecol</i>. 2013a;122(1):176-185. doi:10.1097/01.AOG.0000431815.52679.bb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/23787936/pubmed" id="23787936" target="_blank">23787936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013b;121(4):887-890. doi:10.1097/01.AOG.0000428645.90795.d9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635706">
<a name="23635706"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. <i>Obstet Gynecol</i>. 2013c;121(4):891-896. doi:10.1097/01.AOG.0000428646.67925.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/23635706/pubmed" id="23635706" target="_blank">23635706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812486">
<a name="23812486"></a>American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013d;121:1407-1410. doi:10.1097/01.AOG.0000431053.33593.2d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/23812486/pubmed" id="23812486" target="_blank">23812486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24848921">
<a name="24848921"></a>American College of Obstetricians and Gynecologists (ACOG); Committee on Adolescent Health Care; Committee on Gynecologic Practice. ACOG Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects. <i>Obstet Gynecol</i>. 2014;123(6):1398-1402. doi:10.1097/01.AOG.0000450758.95422.c8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24848921/pubmed" id="24848921" target="_blank">24848921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28426619">
<a name="28426619"></a>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 698: Hormone therapy in primary ovarian insufficiency. <i>Obstet Gynecol.</i> 2017;129(5):e134-e141. doi:10.1097/AOG.0000000000002044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/28426619/pubmed" id="28426619" target="_blank">28426619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25932867">
<a name="25932867"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. <i>Obstet Gynecol</i>. 2015;125(5):1272-1278. doi:10.1097/01.AOG.0000465189.50026.20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/25932867/pubmed" id="25932867" target="_blank">25932867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27454732">
<a name="27454732"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Adolescent Health Care. Committee Opinion No. 668: Menstrual manipulation for adolescents with physical and developmental disabilities. <i>Obstet Gynecol</i>. 2016;128(2):e20-e25. doi:10.1097/AOG.0000000000001585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/27454732/pubmed" id="27454732" target="_blank">27454732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. <i>JAMA</i>. 2004;291(14):1701-12. doi: 10.1001/jama.291.14.1701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11057840">
<a name="11057840"></a>Apgar BS, Greenberg G. Using progestins in clinical practice. <i>Am Fam Physician</i>. 2000;62(8):1839-46, 1849-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/11057840/pubmed" id="11057840" target="_blank">11057840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Medroxy.2014.03">
<a name="Apo-Medroxy.2014.03"></a>Apo-Medroxy (medroxyprogesterone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16904417">
<a name="16904417"></a>Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. <i>Contraception</i>. 2006;74(3):234-238. doi:10.1016/j.contraception.2006.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/16904417/pubmed" id="16904417" target="_blank">16904417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863972">
<a name="22863972"></a>Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia<i>. J Minim Invasive Gynecol</i>. 2012;19(5):562-571. doi:10.1016/j.jmig.2012.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/22863972/pubmed" id="22863972" target="_blank">22863972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32973688">
<a name="32973688"></a>Bachrach LK. Hormonal contraception and bone health in adolescents. <i>Front Endocrinol (Lausanne)</i>. 2020;11:603. doi:10.3389/fendo.2020.00603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32973688/pubmed" id="32973688" target="_blank">32973688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8459515">
<a name="8459515"></a>Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. <i>JAMA</i>. 1993;269(14):1823-1828.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/8459515/pubmed" id="8459515" target="_blank">8459515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33898953">
<a name="33898953"></a>Beksinska M, Issema R, Beesham I, et al. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. <i>EClinicalMedicine</i>. 2021;34:100800. doi:10.1016/j.eclinm.2021.100800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/33898953/pubmed" id="33898953" target="_blank">33898953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32304766">
<a name="32304766"></a>Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: Contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. <i>Contraception</i>. 2020;102(2):70-82. doi:10.1016/j.contraception.2020.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32304766/pubmed" id="32304766" target="_blank">32304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368986">
<a name="11368986"></a>Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. <i>Contraception</i>. 2001;63(3):143-146. doi:10.1016/s0010-7824(01)00181-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/11368986/pubmed" id="11368986" target="_blank">11368986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29142910">
<a name="29142910"></a>Carswell JM, Roberts SA. Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents. <i>Transgend Health</i>. 2017;2(1):195-201. doi:10.1089/trgh.2017.0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/29142910/pubmed" id="29142910" target="_blank">29142910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21734635">
<a name="21734635"></a>Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):878-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/21734635/pubmed" id="21734635" target="_blank">21734635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459439">
<a name="32459439"></a>Chelmow D, Pearlman MD, Young A, et al. Executive summary of the early-onset breast cancer evidence review conference. <i>Obstet Gynecol</i>. 2020;135(6):1457-1478. doi:10.1097/AOG.0000000000003889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32459439/pubmed" id="32459439" target="_blank">32459439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196674">
<a name="19196674"></a>Chlebowski RT, Kuller LH, Prentice RL, et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. <i>N Engl J Med</i>. 2009;360(6):573-87. doi:10.1056/NEJMoa0807684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/19196674/pubmed" id="19196674" target="_blank">19196674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28816933">
<a name="28816933"></a>Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i>. 2018;25(1):11-20. doi: 10.1097/GME.0000000000000956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/28816933/pubmed" id="28816933" target="_blank">28816933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467319">
<a name="27467319"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1‐66. doi: 10.15585/mmwr.rr6504a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/27467319/pubmed" id="27467319" target="_blank">27467319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34014910">
<a name="34014910"></a>Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK. Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate. <i>MMWR Morb Mortal Wkly Rep</i>. 2021;70(20):739-743. doi:10.15585/mmwr.mm7020a2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/34014910/pubmed" id="34014910" target="_blank">34014910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467196">
<a name="27467196"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1‐103. doi:10.15585/mmwr.rr6503a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/27467196/pubmed" id="27467196" target="_blank">27467196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24463911">
<a name="24463911"></a>De Souza MJ, Nattiv A, Joy E, et al; Expert Panel. 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st international conference held in San Francisco, California, May 2012 and 2nd international conference held in Indianapolis, Indiana, May 2013. <i>Br J Sports Med.</i> 2014;48(4):289. doi:10.1136/bjsports-2013-093218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24463911/pubmed" id="24463911" target="_blank">24463911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depo-Provera.2017.04">
<a name="Depo-Provera.2017.04"></a>Depo-Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depo-Provera.2021.12">
<a name="Depo-Provera.2021.12"></a>Depo-Provera (medroxyprogesterone acetate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depo-ProveraCI.2020.12">
<a name="Depo-ProveraCI.2020.12"></a>Depo-Provera CI (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depo-SubQ.2020.12">
<a name="Depo-SubQ.2020.12"></a>Depo-SubQ Provera 104 (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30633132">
<a name="30633132"></a>Dianat S, Fox E, Ahrens KA, et al. Side effects and health benefits of Depot medroxyprogesterone acetate: A systematic review. <i>Obstet Gynecol</i>. 2019;133(2):332-341. doi:10.1097/AOG.0000000000003089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/30633132/pubmed" id="30633132" target="_blank">30633132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6453536">
<a name="6453536"></a>Gagné P. Treatment of sex offenders with medroxyprogesterone acetate. Am J Psychiatry. 1981;138(5):644-6. doi:10.1176/ajp.138.5.644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/6453536/pubmed" id="6453536" target="_blank">6453536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193047">
<a name="22193047"></a>Goodman NF, Cobin RH, Ginzburg SB, et al; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. <i>Endocr Pract</i>. 2011;17(suppl 6):1-25. doi:10.4158/ep.17.s6.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/22193047/pubmed" id="22193047" target="_blank">22193047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368518">
<a name="28368518"></a>Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2017;102(5):1413-1439. doi:10.1210/jc.2017-00131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/28368518/pubmed" id="28368518" target="_blank">28368518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19243704">
<a name="19243704"></a>Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. <i>Clin Ther</i>. 2009;31(1):1-31. doi:10.1016/j.clinthera.2009.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/19243704/pubmed" id="19243704" target="_blank">19243704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative [published correction appearing in <i>Arch Intern Med</i>. 2006;166(7):759]. <i>Arch Intern Med</i>. 2006;166(3):357-65. doi:10.1001/archinte.166.3.357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31019626">
<a name="31019626"></a>Jirakittidul P, Somyaprasert C, Angsuwathana S. Prevalence of documented excessive weight gain among adolescent girls and young women using Depot medroxyprogesterone acetate. <i>J Clin Med Res</i>. 2019;11(5):326-331. doi:10.14740/jocmr3792<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31019626/pubmed" id="31019626" target="_blank">31019626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaunitz.1">
<a name="Kaunitz.1"></a>Kaunitz AM. Abnormal uterine bleeding in nonpregnant reproductive-age patients: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30638562">
<a name="30638562"></a>Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S. No. 313-menstrual suppression in special circumstances. <i>J Obstet Gynaecol Can</i>. 2019;41(2):e7-e17. doi:10.1016/j.jogc.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/30638562/pubmed" id="30638562" target="_blank">30638562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6213373">
<a name="6213373"></a>Koetsawang S, Nukulkarn P, Fotherby K, Shrimanker K, Mangalam M, Towobola K. Transfer of contraceptive steroids in milk of women using long-acting gestagens. <i>Contraception</i>. 1982;25(4):321-331. doi:10.1016/0010-7824(82)90090-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/6213373/pubmed" id="6213373" target="_blank">6213373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31394072">
<a name="31394072"></a>Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. <i>Am J Obstet Gynecol</i>. 2020;222(2):134-143. doi:10.1016/j.ajog.2019.07.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31394072/pubmed" id="31394072" target="_blank">31394072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18390083">
<a name="18390083"></a>Küçük T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. <i>Clin Exp Obstet Gynecol</i>. 2008;35(1):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/18390083/pubmed" id="18390083" target="_blank">18390083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8773423">
<a name="8773423"></a>Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. <i>Contraception</i>. 1996;53(6):357-61. doi:10.1016/0010-7824(96)00085-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/8773423/pubmed" id="8773423" target="_blank">8773423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21768848">
<a name="21768848"></a>Lestishock L, Pariseau C, Rooholamini S, Ammerman S. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl. <i>Obstet Gynecol</i>. 2011;118(2 Pt 2):443-445. doi:10.1097/AOG.0b013e318213cd49<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/21768848/pubmed" id="21768848" target="_blank">21768848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24960023">
<a name="24960023"></a>Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. <i>Cochrane Database Syst Rev</i>. 2014;(6):CD006033. doi:10.1002/14651858.CD006033.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24960023/pubmed" id="24960023" target="_blank">24960023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27567593">
<a name="27567593"></a>Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. <i>Cochrane Database Syst Rev</i>. 2016;2016(8):CD008815. doi:10.1002/14651858.CD008815.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/27567593/pubmed" id="27567593" target="_blank">27567593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16505409">
<a name="16505409"></a>Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. <i>J Clin Oncol</i>. 2006;24(9):1409-1414. doi:10.1200/JCO.2005.04.7324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/16505409/pubmed" id="16505409" target="_blank">16505409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427355">
<a name="18427355"></a>Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. <i>Menopause</i>. 2008;15(4, pt 1):655-660. doi:10.1097/gme.0b013e3181679150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/18427355/pubmed" id="18427355" target="_blank">18427355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martin.1">
<a name="Martin.1"></a>Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32909630">
<a name="32909630"></a>Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. <i>Cochrane Database Syst Rev</i>. 2020;9(9):CD012658. doi:10.1002/14651858.CD012658.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32909630/pubmed" id="32909630" target="_blank">32909630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602689">
<a name="19602689"></a>Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. <i>JAMA</i>. 2009;302(3):298-305. doi:10.1001/jama.2009.1052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/19602689/pubmed" id="19602689" target="_blank">19602689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012455">
<a name="17012455"></a>Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. <i>Obstet Gynecol</i>. 2006;108(4):924-929. doi: 10.1097/01.AOG.0000238343.62063.22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/17012455/pubmed" id="17012455" target="_blank">17012455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196677">
<a name="19196677"></a>Nelson LM. Clinical practice. Primary ovarian insufficiency.<i> N Engl J Med</i>. 2009;360(6):606-614. doi:10.1056/NEJMcp0808697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/19196677/pubmed" id="19196677" target="_blank">19196677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852449">
<a name="32852449"></a>North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. <i>Menopause</i>. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32852449/pubmed" id="32852449" target="_blank">32852449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of the North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24286192">
<a name="24286192"></a>Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. <i>BJOG</i>. 2014;121(4):477-486. doi:10.1111/1471-0528.12499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24286192/pubmed" id="24286192" target="_blank">24286192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24905063">
<a name="24905063"></a>Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. <i>J Clin Endocrinol Metab</i>. 2014;99(9):3418-3426. doi:10.1210/jc.2013-4145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24905063/pubmed" id="24905063" target="_blank">24905063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24630080">
<a name="24630080"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Treatment of pelvic pain associated with endometriosis: a committee opinion. <i>Fertil Steril</i>. 2014;101(4):927-935. doi:10.1016/j.fertnstert.2014.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24630080/pubmed" id="24630080" target="_blank">24630080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30980941">
<a name="30980941"></a>Pradhan S, Gomez-Lobo V. Hormonal contraceptives, intrauterine devices, gonadotropin-releasing hormone analogues and testosterone: menstrual suppression in special adolescent populations. <i>J Pediatr Adolesc Gynecol</i>. 2019;32(5S):S23-S29. doi:10.1016/j.jpag.2019.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/30980941/pubmed" id="30980941" target="_blank">30980941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Provera.2018.09">
<a name="Provera.2018.09"></a>Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY; Pharmacia and Upjohn; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Provera.2014.09">
<a name="Provera.2014.09"></a>Provera (medroxyprogesterone acetate) [product monograph]. Kirkland, Quebec, Canada; Pfizer Canada Inc; September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479152">
<a name="31479152"></a>Quintino-Moro A, Zantut-Wittmann DE, Silva Dos Santos PN, Silva CA, Bahamondes L, Fernandes A. Changes in calcium metabolism and bone mineral density in new users of medroxyprogesterone acetate during the first year of use. <i>Int J Gynaecol Obstet</i>. 2019;147(3):319-325. doi:10.1002/ijgo.12958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31479152/pubmed" id="31479152" target="_blank">31479152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. <i>JAMA</i>. 2002;288(3):321-333. doi:10.1001/jama.288.3.321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046776">
<a name="12046776"></a>Schrager S. Abnormal uterine bleeding associated with hormonal contraception. <i>Am Fam Physician</i>. 2002;65(10):2073-2080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/12046776/pubmed" id="12046776" target="_blank">12046776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. <i>JAMA</i>. 2003;289(20):2651-62. doi:10.1001/jama.289.20.2651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29694506">
<a name="29694506"></a>Silva P, Qadir S, Fernandes A, Bahamondes L, Peipert JF. Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review. <i>Braz J Med Biol Res</i>. 2018;51(6):e7575. doi:10.1590/1414-431x20187575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/29694506/pubmed" id="29694506" target="_blank">29694506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11156873">
<a name="11156873"></a>Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). <i>Circulation</i>. 2001;103(5):638-642. doi:10.1161/01.cir.103.5.638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/11156873/pubmed" id="11156873" target="_blank">11156873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31928370">
<a name="31928370"></a>Sims J, Lutz E, Wallace K, Kassahun-Yimer W, Ngwudike C, Shwayder J. Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women. <i>Eur J Contracept Reprod Health Care</i>. 2020;25(1):54-59. doi:10.1080/13625187.2019.1709963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/31928370/pubmed" id="31928370" target="_blank">31928370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538049">
<a name="21538049"></a>Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. <i>Rev Endocr Metab Disord</i>. 2011;12(2):63-75. doi:10.1007/s11154-011-9182-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/21538049/pubmed" id="21538049" target="_blank">21538049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32041389">
<a name="32041389"></a>Sophie Gibson ME, Fleming N, Zuijdwijk C, Dumont T. Where have the periods gone? The evaluation and management of functional hypothalamic amenorrhea.<i> J Clin Res Pediatr Endocrinol.</i> 2020;12(suppl 1):18-27. doi:10.4274/jcrpe.galenos.2019.2019.S0178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/32041389/pubmed" id="32041389" target="_blank">32041389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20459370">
<a name="20459370"></a>Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM; WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. <i>World J Biol Psychiatry</i>. 2010;11(4):604-55. doi:10.3109/15622971003671628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/20459370/pubmed" id="20459370" target="_blank">20459370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561210">
<a name="10561210"></a>Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. <i>J Clin Oncol</i>. 1999;17(6):1736-44. doi:10.1200/JCO.1999.17.6.1736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/10561210/pubmed" id="10561210" target="_blank">10561210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090535">
<a name="23090535"></a>Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. <i>Obstet Gynecol</i>. 2012;120(5):1160-1175. doi:10.1097/aog.0b013e31826bb121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/23090535/pubmed" id="23090535" target="_blank">23090535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2016">
<a name="USHHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016. .</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8899256">
<a name="8899256"></a>Virutamasen P, Leepipatpaiboon S, Kriengsinyot R, et al. Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants. <i>Contraception</i>. 1996;54(3):153-157. doi:10.1016/s0010-7824(96)00170-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/8899256/pubmed" id="8899256" target="_blank">8899256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24784333">
<a name="24784333"></a>Yancey JR, Raleigh M. Progestin-only contraceptives: effects on weight. <i>Am Fam Physician</i>. 2014;89(9):715-716.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medroxyprogesterone-acetate-pediatric-drug-information/abstract-text/24784333/pubmed" id="24784333" target="_blank">24784333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zacur.1">
<a name="Zacur.1"></a>Zacur HA. Managing an episode of acute uterine bleeding. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed October 20, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12577 Version 367.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
